Biogen Inc. vs Samsung Electronics Co., Ltd.: Strategic Comparison

This in-depth comparison examines Biogen Inc. and Samsung Electronics Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Biogen Inc. on its own, evaluating Samsung Electronics Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Biogen Inc. and Samsung Electronics Co., Ltd. is widest.

On the headline numbers, Biogen Inc. reports annual revenue of $9.9B against ~$236.9B for Samsung Electronics Co., Ltd., while their respective market capitalizations stand at $33.4B and $1.33T. Biogen Inc. is headquartered in United States and Samsung Electronics Co., Ltd. in South Korea, and those different home markets shape how each company competes.

Biogen Inc.: Biogen is one of the oldest independent biotechnology companies, known for multiple sclerosis drugs (Avonex, Tysabri, Tecfidera, Vumerity), the first approved spinal muscular atrophy treatment (Spinraza) and the Alzheimer's antibodies Aduhelm and Leqembi. It trades on Nasdaq as BIIB, is an S&P 500 member and is headquartered at 225 Binney Street in Cambridge, Massachusetts. Since 2023 it has broadened from neurology into rare disease, immunology, nephrology and eye disease, mainly through acquisitions.

Samsung Electronics Co., Ltd.: Samsung Electronics, based in Suwon, is the flagship company of the Samsung Group and South Korea's most valuable listed company. It is the world's largest memory chipmaker and one of the two largest smartphone vendors. Its market value passed $1 trillion in May 2026 and was about $1.33 trillion in late September 2026, after its shares more than tripled in a year on AI memory demand. The company is led by co-CEOs Jun Young-hyun (semiconductors) and TM Roh (devices), with Jay Y. Lee as Executive Chairman.

Biogen Inc. and Samsung Electronics Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Biogen Inc. and Samsung Electronics Co., Ltd..

Biogen Inc. business model: Biogen discovers, licenses or acquires drug candidates, runs the clinical trials needed for approval, manufactures most of its biologics in Research Triangle Park, North Carolina and Solothurn, Switzerland, and sells approved products through specialty pharmacies, hospitals and infusion centers. Revenue comes from three places: product sales (about 70% of Q2 2026 revenue, led by Tysabri, Spinraza, Vumerity, Skyclarys, Syfovre and Zurzuvae), royalties and profit share on Genentech's anti-CD20 drugs such as Ocrevus ($514 million in Q2 2026), and its share of Leqembi economics with Eisai plus contract manufacturing. Prices are high because the diseases are severe and patient groups small: Spinraza launched at about $750,000 for the first year of treatment. Many assets are partnered, so Biogen shares costs and profits with Eisai, Ionis, UCB, Supernus and others.

Samsung Electronics Co., Ltd. business model: Samsung earns money from two groups of businesses. Device Solutions (DS) makes and sells memory (DRAM, HBM, NAND), System LSI chips such as Exynos processors and ISOCELL image sensors, and contract foundry manufacturing. In Q2 2026, DS produced ~$90.5 billion (KRW 127.5 trillion) of the company's ~$122 billion (KRW 171.5 trillion) revenue and ~$63.3 billion (KRW 89.2 trillion) of its ~$63.5 billion (KRW 89.5 trillion) operating profit. Device eXperience (DX) sells Galaxy phones, tablets, wearables, TVs, monitors and home appliances, plus network equipment. Separately consolidated subsidiaries add OLED panels from Samsung Display, sold to Apple and other phone makers, and automotive and audio electronics from Harman.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Biogen Inc. stack up against those of Samsung Electronics Co., Ltd..

Biogen Inc. competitive advantage: Biogen's edge is more than four decades of neurology experience: relationships with neurologists and MS and SMA treatment centers, experience running long central nervous system trials, antisense know-how built with Ionis (Spinraza, Qalsody, salanersen and diranersen all came from that alliance) and in-house biologics manufacturing. Royalty income from Ocrevus and cash flow from mature drugs, $2.1 billion of free cash flow in 2025, fund acquisitions such as Reata and Apellis with cash and debt rather than new shares.

Samsung Electronics Co., Ltd. competitive advantage: Samsung's edge is manufacturing scale and breadth. It is the largest memory producer and one of only three major DRAM makers, alongside SK hynix and Micron. That lets it capture pricing upswings like the 2026 AI-driven shortage. It also owns component businesses (memory, OLED through Samsung Display, image sensors) that sell to rivals as well as to its own Galaxy devices, so it earns money even when competitors' products win.

Future prospects matter as much as current results. The growth strategies below explain how Biogen Inc. and Samsung Electronics Co., Ltd. each plan to expand from here.

Biogen Inc. growth strategy: Viehbacher's plan has three parts. First, cut costs: the Fit for Growth program launched in 2023 targeted about $1 billion of gross savings and removed roughly 1,000 roles. Second, launch newer drugs such as Leqembi, Skyclarys, Zurzuvae and Qalsody; the growth portfolio reached $1.1 billion of revenue in Q2 2026, up 24%. Third, buy late-stage or commercial assets beyond core neurology: Reata ($7.3 billion, 2023), HI-Bio ($1.15 billion upfront, 2024) and Apellis (about $5.6 billion, 2026), which together move Biogen into rare disease, immunology, nephrology and ophthalmology.

Samsung Electronics Co., Ltd. growth strategy: Samsung's growth plan centers on AI memory: ramping HBM4 for Nvidia and AMD accelerators, developing HBM4E, and adding DRAM capacity at Pyeongtaek. In foundry it is pursuing 2nm gate-all-around production and building its Taylor, Texas fab to win customers from TSMC. On the device side it relies on Galaxy AI features, foldables and premium TVs to defend share against Apple and Chinese brands.

A closer look at the financial trajectory of Biogen Inc. and Samsung Electronics Co., Ltd. rounds out the comparison.

Biogen Inc.: Biogen's revenue peaked at $14.38 billion in 2019, then fell to $9.84 billion by 2023 as generic dimethyl fumarate eroded Tecfidera after a 2020 US patent loss and as Aduhelm failed commercially. It has since stabilised at $9.68 billion in 2024 and $9.89 billion in 2025, when GAAP diluted EPS was $8.79, non-GAAP EPS $15.28, free cash flow $2.1 billion and year-end cash $4.2 billion. Q2 2026 revenue rose 3% to $2.74 billion. Funding the Apellis deal took net debt to $6.8 billion, and 2026 non-GAAP EPS guidance of $12 to $13 absorbs about $3 per share of milestone charges and $0.85 of deal dilution.

Samsung Electronics Co., Ltd.: Samsung's earnings follow the memory cycle. Revenue fell from ~$215 billion (KRW 302.2 trillion) in 2022 to ~$184 billion (KRW 258.9 trillion) in 2023 during a chip downturn, then recovered to ~$214 billion (KRW 300.9 trillion) in 2024 and ~$237 billion (KRW 333.6 trillion) in 2025, when net income reached about $31.5 billion (KRW 44.3 trillion). In 2026, AI server demand created a memory shortage. Q1 operating profit of ~$40.6 billion (KRW 57.2 trillion) exceeded the full-year 2025 total, and Q2 reached ~$63.5 billion (KRW 89.5 trillion) on ~$122 billion (KRW 171.5 trillion) revenue. Higher memory costs also squeezed Samsung's own devices: the MX and Networks unit lost ~$497 million (KRW 0.7 trillion) in Q2 2026 on ~$23.6 billion (KRW 33.2 trillion) revenue.